MD1521F2 - Metode de inhibare a formarii de trombi, metode de tratament al starilor trombotice, compozitii farmaceutice si trusa pentru tratamentul starilor trombotice - Google Patents

Metode de inhibare a formarii de trombi, metode de tratament al starilor trombotice, compozitii farmaceutice si trusa pentru tratamentul starilor trombotice Download PDF

Info

Publication number
MD1521F2
MD1521F2 MD96-0334A MD960334A MD1521F2 MD 1521 F2 MD1521 F2 MD 1521F2 MD 960334 A MD960334 A MD 960334A MD 1521 F2 MD1521 F2 MD 1521F2
Authority
MD
Moldova
Prior art keywords
treatment
methods
thrombotic states
kit
pharmaceutical compositions
Prior art date
Application number
MD96-0334A
Other languages
English (en)
Other versions
MD960334A (ro
MD1521G2 (ro
Inventor
Paul E Gargan
Original Assignee
American Biogenetic Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences filed Critical American Biogenetic Sciences
Publication of MD960334A publication Critical patent/MD960334A/ro
Publication of MD1521F2 publication Critical patent/MD1521F2/ro
Publication of MD1521G2 publication Critical patent/MD1521G2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MD96-0334A 1994-02-24 1995-02-21 Metode de inhibare a formării de trombi, metode de tratament al stărilor trombotice, compoziţii farmaceutice şi trusă pentru tratamentul stărilor trombotice MD1521G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/204,015 US5487892A (en) 1994-02-24 1994-02-24 Method for treating thrombotic disease using a fibrin specific monoclonal antibody
PCT/US1995/001825 WO1995022986A1 (en) 1994-02-24 1995-02-21 Fibrin-specific antibody for use as an antithrombotic agent

Publications (3)

Publication Number Publication Date
MD960334A MD960334A (ro) 1997-09-30
MD1521F2 true MD1521F2 (ro) 2000-08-31
MD1521G2 MD1521G2 (ro) 2001-03-31

Family

ID=22756260

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0334A MD1521G2 (ro) 1994-02-24 1995-02-21 Metode de inhibare a formării de trombi, metode de tratament al stărilor trombotice, compoziţii farmaceutice şi trusă pentru tratamentul stărilor trombotice

Country Status (26)

Country Link
US (1) US5487892A (ro)
EP (1) EP0749320A4 (ro)
JP (1) JPH09509429A (ro)
KR (1) KR970701063A (ro)
CN (1) CN1146157A (ro)
AU (1) AU708897B2 (ro)
BG (1) BG62476B1 (ro)
BR (1) BR9506949A (ro)
CA (1) CA2183953A1 (ro)
CZ (1) CZ246496A3 (ro)
FI (1) FI963288A7 (ro)
GE (1) GEP20002257B (ro)
HU (1) HUT76536A (ro)
LT (1) LT4192B (ro)
LV (1) LV11784B (ro)
MD (1) MD1521G2 (ro)
MX (1) MX9603602A (ro)
NO (1) NO963497L (ro)
NZ (1) NZ281481A (ro)
PL (1) PL316005A1 (ro)
RU (1) RU2152801C2 (ro)
SG (1) SG53279A1 (ro)
SK (1) SK108496A3 (ro)
TJ (1) TJ301B (ro)
UA (1) UA41984C2 (ro)
WO (1) WO1995022986A1 (ro)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL134828A0 (en) * 2000-03-01 2001-05-20 Eship 4U Com Inc System for delivery and receipt of dispatches especially useful for e-commerce
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
JP4088328B2 (ja) * 2004-12-28 2008-05-21 第一化学薬品株式会社 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
CN110563258A (zh) * 2019-09-06 2019-12-13 广东石油化工学院 一种猪场废水厌氧产氢与达标排放处理方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
WO1988001514A1 (en) * 1986-08-25 1988-03-10 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5223410A (en) * 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
SG50681A1 (en) * 1988-06-13 1998-07-20 American Biogenetic Sciences Method for the production of monoclonal antibodies utilizing a germfree animal
US5091512A (en) * 1988-06-13 1992-02-25 American Biogenetic Sciences, Inc. Fibrinogen-specific monoclonal antibody
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use

Also Published As

Publication number Publication date
FI963288A0 (fi) 1996-08-23
NO963497L (no) 1996-10-16
HU9602337D0 (en) 1996-10-28
LV11784B (en) 1997-12-20
LT4192B (en) 1997-07-25
CN1146157A (zh) 1997-03-26
KR970701063A (ko) 1997-03-17
MX9603602A (es) 1997-05-31
EP0749320A4 (en) 1997-06-18
BG100863A (en) 1997-08-29
HUT76536A (en) 1997-09-29
CZ246496A3 (en) 1997-04-16
MD960334A (ro) 1997-09-30
MD1521G2 (ro) 2001-03-31
PL316005A1 (en) 1996-12-23
JPH09509429A (ja) 1997-09-22
FI963288L (fi) 1996-08-23
RU2152801C2 (ru) 2000-07-20
LV11784A (lv) 1997-06-20
WO1995022986A1 (en) 1995-08-31
NZ281481A (en) 1998-07-28
NO963497D0 (no) 1996-08-22
SK108496A3 (en) 1997-10-08
UA41984C2 (uk) 2001-10-15
BR9506949A (pt) 1997-09-23
AU1843495A (en) 1995-09-11
AU708897B2 (en) 1999-08-12
US5487892A (en) 1996-01-30
TJ301B (en) 2001-08-06
SG53279A1 (en) 1998-09-28
FI963288A7 (fi) 1996-08-23
EP0749320A1 (en) 1996-12-27
LT96140A (en) 1997-03-25
BG62476B1 (bg) 1999-12-30
GEP20002257B (en) 2000-10-25
CA2183953A1 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
AU578428B2 (en) Trace-labeled conjugates of metallothionein and target- seeking biologically active molecules
BG105435A (en) Stable liquid formulations of botulinum toxin
MD1367C2 (ro) Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
HU9700056D0 (en) New pharmaceutical composition for treating pains
DE69617469D1 (de) Behandlung von multipler sklerose
ZA943744B (en) Therapeutic substituted guanidines
MD1521F2 (ro) Metode de inhibare a formarii de trombi, metode de tratament al starilor trombotice, compozitii farmaceutice si trusa pentru tratamentul starilor trombotice
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
SE9603725D0 (sv) New teatment
CA2408541A1 (en) Treating eczema and/or psoriasis
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
SE9601395D0 (sv) New therapeutic treatment 1
KR960704933A (ko) 난치성 동통에 대한 진통제 및 완화제로서의 릴렉신의 용도
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
MY133181A (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
RU95110382A (ru) Способ лечения воспалительных заболеваний женских половых органов в репродуктивном возрасте
IT1255469B (it) Uso della n-acetil-cisteina nella prevenzione e nel trattamento della discinesia tardiva
UA15177C2 (uk) Засіб для лікуваhhя уражеhь слизової травhого тракту
UA30125A (uk) Спосіб лікування дітей з ревматоїдним артритом та дифузними хворобами сполучної тканини
KR970005296A (ko) 편도선염 치료제

Legal Events

Date Code Title Description
PD99 Pending application